Accession Number:

ADA429608

Title:

Post-Renal Transplant Thrombotic Thrombocytopenic Purpura (TTP): Attributable to Immunosuppression or Graft Rejection? Report of Three Cases and Literature Review

Descriptive Note:

Corporate Author:

YALE UNIV NEW HAVEN CT SCHOOL OF MEDICINE

Report Date:

2005-01-25

Pagination or Media Count:

28.0

Abstract:

The immunomodulatory drug FK-506 Tacrolimus is a calcineurin inhibitor that, as such, indirectly inhibits the transcription of a gene encoding interleukin 2, a cytokine that is vital to the immune response process. Since its introduction in 1987, sporadic reports have appeared describing the development of thrombotic thrombocytopenic purpura TTP - or a similar syndrome - in patients taking this drug. Sirolimus Rapamune is another immunomodulatory drug with a more favorable side-effects profile than calcineurin inhibitors.

Subject Categories:

  • Anatomy and Physiology
  • Medicine and Medical Research
  • Microbiology

Distribution Statement:

APPROVED FOR PUBLIC RELEASE